NCI has established a program at Frederick National Laboratory to manufacture CAR T-cell therapies for multicenter clinical trials.
Late in 1997, when Bruce Ross told me that Bill McGivney would replace him as CEO of the National Comprehensive Cancer Network, I thought the recruitment made sense.
Cancer History Project editorial board member Robert Peter Gale shares his perspective on the Fukushima Daiichi nuclear accident, marking the 10th anniversary of the disaster.
FDA will hold a three-day meeting of the Oncologic Drugs Advisory Committee April 27-29 to consider five indications that received accelerated approvals, but that have not been shown to produce a clinical benefit in confirmatory trials.
NCI recently announced a master plan for its $500 million Childhood Cancer Data Initiative, a pilot project designed to set the stage for building a publicly accessible, comprehensive data federation for all cancers (The Cancer Letter, Dec. 4, 2020).
The National Comprehensive Cancer Network, an organization that promulgates guidelines based on standards of care provided at academic institutions in the U.S., is indisputably one of the pillars of oncology today.
This column in The Cancer Letter features the latest posts to the Cancer History Project by our growing list of contributors.
Last year, Fox Chase Cancer Center stood poised to make history by becoming the first NCI-designated cancer center to be sold on open market.
Three companies withdraw cancer indications for PD-1/PD-L1 drugs in FDA’s “industry-wide evaluation”
Over the past three months, three pharmaceutical companies voluntarily withdrew three cancer indications for drugs that had previously received accelerated approvals from FDA, but ultimately failed to meet agreed-upon endpoints in confirmatory trials required for regular approvals.
Once an expensive cancer drug is discarded, it’s not worth it for drug developers, health care providers, and payers to recoup its cost, the National Academies of Sciences, Engineering, and Medicine said in a congressionally mandated report.
